Literature DB >> 11307797

NF-kappa B may determine whether epithelial cell--microbial interactions in the intestine are hostile or friendly.

Y R Mahida, S Johal.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11307797      PMCID: PMC1906004          DOI: 10.1046/j.1365-2249.2001.01470.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  25 in total

1.  NF-kappa B is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria.

Authors:  D Elewaut; J A DiDonato; J M Kim; F Truong; L Eckmann; M F Kagnoff
Journal:  J Immunol       Date:  1999-08-01       Impact factor: 5.422

Review 2.  A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways.

Authors:  T Maniatis
Journal:  Genes Dev       Date:  1999-03-01       Impact factor: 11.361

Review 3.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses.

Authors:  S Ghosh; M J May; E B Kopp
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

4.  Bacteroides fragilis toxin 2 damages human colonic mucosa in vitro.

Authors:  M Riegler; M Lotz; C Sears; C Pothoulakis; I Castagliuolo; C C Wang; R Sedivy; T Sogukoglu; E Cosentini; G Bischof; W Feil; B Teleky; G Hamilton; J T LaMont; E Wenzl
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

5.  Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.

Authors:  B J Rembacken; A M Snelling; P M Hawkey; D M Chalmers; A T Axon
Journal:  Lancet       Date:  1999-08-21       Impact factor: 79.321

6.  The Bacteroides fragilis toxin fragilysin disrupts the paracellular barrier of epithelial cells.

Authors:  R J Obiso; A O Azghani; T D Wilkins
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

7.  Interleukin-8 controls bacterial transepithelial translocation at the cost of epithelial destruction in experimental shigellosis.

Authors:  P J Sansonetti; J Arondel; M Huerre; A Harada; K Matsushima
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

8.  Heterogeneity in responses by primary adult human colonic epithelial cells to purified enterotoxin of Bacteroides fragilis.

Authors:  L Sanfilippo; T J Baldwin; M G Menozzi; S P Borriello; Y R Mahida
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

9.  Bacteroides fragilis enterotoxin cleaves the zonula adherens protein, E-cadherin.

Authors:  S Wu; K C Lim; J Huang; R F Saidi; C L Sears
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

10.  Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells.

Authors:  E DiMango; A J Ratner; R Bryan; S Tabibi; A Prince
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

View more
  5 in total

Review 1.  Paneth cells: their role in innate immunity and inflammatory disease.

Authors:  D A Elphick; Y R Mahida
Journal:  Gut       Date:  2005-12       Impact factor: 23.059

Review 2.  Biologic therapy for inflammatory bowel disease.

Authors:  Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Bacteroides fragilis enterotoxin induces intestinal epithelial cell secretion of interleukin-8 through mitogen-activated protein kinases and a tyrosine kinase-regulated nuclear factor-kappaB pathway.

Authors:  Shaoguang Wu; Jan Powell; Nes Mathioudakis; Sheryl Kane; Ellen Fernandez; Cynthia L Sears
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

4.  Robustaflavone Isolated from Nandina domestica Using Bioactivity-Guided Fractionation Downregulates Inflammatory Mediators.

Authors:  Ara Jo; Hyun Ji Yoo; Mina Lee
Journal:  Molecules       Date:  2019-05-08       Impact factor: 4.411

5.  Biologic targeting in the treatment of inflammatory bowel diseases.

Authors:  Matteo Bosani; Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Biologics       Date:  2009-07-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.